A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients With History of HPV16 Associated Cervical Cancer
Latest Information Update: 06 Mar 2025
At a glance
- Drugs Human papillomavirus vaccine (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
Most Recent Events
- 04 Mar 2025 Status changed from active, no longer recruiting to completed.
- 10 Jul 2024 Planned End Date changed from 31 Dec 2024 to 31 Jan 2025.
- 10 Jul 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Dec 2024.